Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

Radiopharm Theranostics’ RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate MZE829, in treating subjects with AKD ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Lilly has revealed that subjects with Crohn's disease have achieved long-term clinical and endoscopic outcomes with Omvoh in the VIVID-2.

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.